Further, the V617F mutant of JAK2 is the causative mutation in approximately 50% of patients with the myeloproliferative disorder, essential thrombocythemia (ET), which is characterized by an increase in platelet count [11−13]. The gene discussed is JAK2; the disease is essential thrombocythemia.